Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Matsutake polypeptide and matsutake extract, and application thereof

A matsutake extract and drug technology, applied in the field of matsutake peptides, can solve problems such as side effects, taste dysfunction, etc., and achieve the effect of enriching the screening library and significant application value

Inactive Publication Date: 2015-10-14
CHINA AGRI UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since the first orally effective synthetic ACE inhibitor Captopril (Captorip) was approved for use in 1981, ACE inhibitors currently used in clinical practice have been very common, but artificially synthesized ACE inhibitors have not been used in clinical applications. Often produces side effects such as cough, taste disturbance, rash, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Matsutake polypeptide and matsutake extract, and application thereof
  • Matsutake polypeptide and matsutake extract, and application thereof
  • Matsutake polypeptide and matsutake extract, and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Embodiment 1, matsutake crude extract and its antihypertensive effect

[0036] 1. Preparation of matsutake crude extract

[0037] 1 part by mass of distilled water and 2 parts by mass of matsutake fruiting bodies were fully crushed into a homogenate, left standing at 4°C for 12 hours, then centrifuged at 8000 g for 15 minutes, and the supernatant was collected and freeze-dried to obtain a matsutake extract.

[0038] Every 14.52g matsutake fruiting body can get 400mg matsutake crude extract.

[0039] 2. Antihypertensive effect of matsutake extract on rats with essential hypertension (single-dose short-term experiment)

[0040] 1. Experimental animals

[0041] Primary hypertensive rats, male, 12 weeks old, body weight 240-270g. Animal testing facilities continue to maintain barrier environmental standards. The control range of the main environmental indicators: temperature 25±2℃, relative humidity 55±5%, light: dark=12h:12h. Animals were kept in standard boxes, with ...

Embodiment 2

[0051] Embodiment 2, discovery of matsutake polypeptide

[0052] 1. Determination of ACE inhibitory activity

[0053] 1. Preparation of ACE solution

[0054] Take 5 g of fresh rabbit lungs with connective tissue removed, wash them with pre-cooled normal saline, cut them into small pieces, and place them in 45 mL of pre-cooled sodium borate buffer containing 0.25 mM sucrose and 0.1 mM PMSF (pH 8.3, 0.1 M ), the homogenate was placed in sodium borate buffer (pH8.3, 0.1M) and dialyzed at 4°C for 12 hours, then centrifuged at 4°C and 9000g for 40 minutes, and the supernatant was collected, and the supernatant was 4°C and 9000g Centrifuge for 40 minutes, collect the supernatant (the supernatant is the ACE solution), and store it at -20°C for later use.

[0055] 2. Determination of ACE inhibitory activity (ACE reacts with HHL to generate hippuric acid, and the ACE inhibitory activity is estimated by the amount of hippuric acid produced)

[0056] 1. Mix 20 μL of the ACE solution p...

Embodiment 3

[0076] Example 3, the antihypertensive effect of matsutake polypeptide on essential hypertensive rats (single-dose short-term experiment)

[0077] The matsutake polypeptide shown in sequence 1 of the sequence listing was artificially synthesized (Shanghai Botai Biotechnology Co., Ltd.).

[0078] 1. Experimental animals

[0079] Primary hypertensive rats, male, 12 weeks old, body weight 240-270g. Animal testing facilities continue to maintain barrier environmental standards. The control range of the main environmental indicators: temperature 25±2℃, relative humidity 55±5%, light: dark=12h:12h. Animals were kept in standard boxes, with 2 rats per box. The sterilized bedding and cages were replaced twice a week, the environment inside the box was kept clean and dry, feed and drinking water were added daily, and animals were kept free to eat and drink. Quarantine and domestication process: The quarantine period for newly received animals is 3-6 days. During the quarantine per...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a matsutake polypeptide and a matsutake extract, and application thereof. The polypeptide disclosed by the invention is derived from matsutake and named matsutake polypeptide, which is disclosed as Sequence 1 in the sequence table. The matsutake extract containing the matsutake polypeptide also belongs to the protection range of the invention. The preparation method of the matsutake extract comprises the following steps: (1) adding matsutake sporophores into water, homogenizing, and extracting; and (2) after finishing the step (1), centrifuging and collecting the supernatant. The polypeptide disclosed by the invention is derived from food, thereby enriching the hypotensive drug screening library and providing theoretical references for further development of matsutake. The matsutake polypeptide and matsutake extract have significant application value for treating hypertension.

Description

technical field [0001] The invention relates to a matsutake polypeptide, a matsutake extract containing the matsutake polypeptide and applications thereof. Background technique [0002] According to the updated data of the World Health Organization (WHO) in 2014, the number of deaths caused by cardiovascular diseases ranks first among the top ten causes of death in the world. An important risk factor for cardiovascular diseases is high blood pressure. With the improvement of living standards and changes in people's lifestyles, the prevalence of high blood pressure is not only increasing, but also tends to be younger. The report on cardiovascular diseases in China shows that there are more than 200 million people with high blood pressure in my country, and the incidence rate is about 17%. (Progress in individualized treatment of hypertension - China Health Yearbook 2009). In addition to the hazards of hypertension itself to human health, the health damage caused by hypertensi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/06C07K1/14A61K38/08A61K38/02A61P9/12
Inventor 王贺祥耿雪冉张薇薇胡玉净刘芹赵爽袁翔鹤
Owner CHINA AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com